Extended therapy and secondary prevention of venous thromboembolic complications

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Venous thromboembolic complications (VTEC) are acute and time-limited diseases. However, the recurrence rate after a first episode of VTEC is high and potentially life-threatening. Developed deep vein thrombosis (DVT) and thromboembolism of pulmonary artery (TEPA) are inevitably associated with use of anticoagulant therapy (ACT). A peculiarity of the modern clinical management of patients with VTEC is determination of duration of ACT.

Aim. To study possibilities of prolonged anticoagulation therapy and secondary prevention of venous thromboembolic complications taking into consideration modern variants of drug therapy, on the basis of literature data.

Search for literature was conducted in Medline and Elibrary databases including materials published in 2020. Randomized clinical and observational studies and meta-analyses, concerning prolonged therapy and secondary prevention of VTEC with vitamin K antagonists (VKA), peroral anticoagulants (POAC), sulodexide and aspirin, were analyzed. As it is evidenced by patho-physiological and epidemiological data, risk of VTEC recurrence in most patients is not resolved after the first 6 months of treatment with anticoagulants. In such situations it is reasonable to prolong anticoagulation for an indefinite period of time. However, sometimes a limiting factor for prolonged therapy with anticoagulants is bleedings caused by prolonged anticoagulation, sometimes leading to lethal outcome. Therefore, duration of treatment in the long-term period after an acute episode may rest on the balance between the risk of development of recurrence of venous thrombosis and bleeding, evaluated with the help of scales. The main achievement of recent years regarding prolonged therapy and secondary prevention of VTEC, are POAC, which in fact are new and alternative drugs that permitted the emergence of serious evidential basis in the range of means for treatment of this category of patients, sulodexide drug has appeared characterized by the minimal rate of development of large and clinically significant bleedings.

Conclusion. The emergence of serious evidential basis for POAC with improved safety profiles, different pharmacokinetic profiles and dosage regimens, including sulodexide that has been actively used in recent years for secondary prevention of VTEC, will permit clinicians to differentially approach treatment of different clinical variants of venous thrombosis, to improve the results of therapy taking into account evaluation of the individual risk and comorbid diseases, and compliance of patients.

About the authors

Alexey S. Petrikov

Altai State Medical University

Author for correspondence.
Email: petricov_alex@mail.ru
ORCID iD: 0000-0002-6501-3289
SPIN-code: 4612-6452

MD, PhD, Professor of the Department of Faculty Surgery named after Professor I.I. Neymark, Hospital Surgery with a Course of Surgery of Additional Professional Education

Russian Federation, Barnaul

Igor I. Prostov

Rostov State Medical University

Email: petricov_alex@mail.ru
ORCID iD: 0000-0002-7853-6775
SPIN-code: 5706-3190

MD, PhD, Associate Professor of the Department of Hospital Surgery №1, Head of the Vascular Surgery Department

Russian Federation, Rostov-on-Don

References

  1. Heit JA. Epidemiology of venous thromboembolism. Nature Reviews. Cardiology. 2015;12(8):464-74. doi: 10.1038/nrcardio.2015.83
  2. Bokeriya LA, Zatevakhin II, Kiriyenko AI, et al. Rossiyskiye klinicheskiye rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy (VTEO). Flebologiya. 2015;9(4-2):1-52. (In Russ).
  3. Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Obshchaya zabolevayemost’ vzroslogo naseleniya Rossii v 2017 godu. In: Statisticheskiy sbornik 2017 god. Moscow; 2018. Suppl. 4. Available at: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisti-cheskiy-sbornik-2017-god. Accessed: 2020 July 25. (In Russ).
  4. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Archives of Internal Medicine. 2000; 160(60): 761-8. doi: 10.1001/archinte.160.6.761
  5. Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. Journal of Thrombosis and Haemostasis. 2016;14(12):2402-9. doi: 10.1111/jth.13524
  6. Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Annals of Internal Medicine. 2002;137(12):955-60. doi: 10.7326/0003-4819-137-12-200212170-00008
  7. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205. doi:10.3324/ haematol.10516
  8. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032-9. doi: 10.1016/S0140-6736(10)60962-2
  9. Verso M, Agnelli G, Ageno W, et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thrombosis Research. 2012;130(3):369-73. doi: 10.1016/j.thromres.2012.04.003
  10. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2): 315-52. doi: 10.1016/j.chest.2015.11.026
  11. Mearns ES, Coleman CI, Patel D, et al. Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2015;13(6):1043-52. doi: 10.1111/jth.12914
  12. Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wiener Klinische Wochenschrift. 2003;115(13-14):471-4. doi: 10.1007/BF03041030
  13. Iorio A, Kearon C, Filippucci E, et al. Risk of
  14. recurrence after a first episode of symptomatic
  15. venous thromboembolism provoked by a transient risk factor: a systematic review. Archives of Internal Medicine. 2010;170(19):1710-6. doi: 10.1001/archinternmed.2010.367
  16. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011;342:d3036. doi: 10.1136/bmj.d3036
  17. Kearon C, Akl EА, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 suppl):e419S-94S. doi: 10.1378/chest.11-2301
  18. Agnelli G, Becattini C. Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. Hematology. 2013;2013 (1):471-7. doi: 10.1182/asheducation-2013.1.471
  19. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Seminars in Thrombosis and Hemostasis. 2012;38(5): 535-48. doi: 10.1055/s-0032-1315758
  20. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American Journal of Medicine. 1993; 95(3):315-28. doi: 10.1016/0002-9343(93)90285-w
  21. Heit JA. Predicting the Risk of Venous Thrombo-embolism Recurrence. American Journal of Hematology. 2012;87(Suppl 1):S63-7. doi: 10.1002/ajh.23128
  22. Sode BF, Allin KH, Dahl M, et al. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. CMAJ. 2013;185(5):E229-37. doi: 10.1503/cmaj.121636
  23. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(Suppl 6):454S-545S. doi: 10.1378/chest.08-0658
  24. Kim K, Yamashita Y, Morimoto T, et al. Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry. Thrombosis and Haemostasis. 2019;119(9):1498-507. doi: 10.1055/s-0039-1692425
  25. Kaatz S, Qureshi W, Fain C, et al. Duration of anti-coagulation treatment in patients with venous thromboembolism. The Journal of the American Osteopathic Association. 2010;110(11):638-44.
  26. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-6. doi: 10.1161/CIRCULATIONAHA.109.925214
  27. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-26. doi: 10.1503/cmaj.080493
  28. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis. 2012;10(6):1019-25. doi: 10.1111/j.1538-7836.2012.04735.x
  29. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126(4):448-54. doi: 10.1161/CIRCULATIONAHA.111.051920
  30. Rodger MA, Le Gal. G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065. doi: 10.1136/bmj.j1065
  31. Kiriyenko AI, Panchenko EP, Andriyashkin VV. Venoznyy tromboz v praktike terapevta i khirurga. Moscow: Planida; 2012. (In Russ).
  32. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. The New England Journal of Medicine. 2013;368(8):709-18. doi: 10.1056/NEJMoa1113697
  33. auersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine. 2010; 363(26):2499-510. doi: 10.1056/NEJMoa1007903
  34. Marcucci M, Iorio A, Douketis JD, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis. 2015; 13(5):775-81. doi: 10.1111/jth.12871
  35. Jiang QJ, Bai J, Jin J, et al. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2018;(9):876. doi: 10.3389/fphar.2018.00876.eCollection 2018
  36. Petrikov AS, Dudin DV, Zaitsev SV, et al. The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs. Statsionarozameshchayushchiye Tekhnologii: Ambulatornaya Khirurgiya. 2018;(3-4):83-8. doi: 10.21518/1995-1477-2018-3-4-83-88
  37. Petricov AS, Dudin DV, Valova OV, et al. Possibilities of long-lasting anti-thrombotic therapy in patients with proximal thrombosis of lower limbs deep veins. Vestnik SurGU. Medicina. 2018;(2):37-43. (In Russ).
  38. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine. 2013;368 (8):699-708. doi: 10.1056/NEJMoa1207541
  39. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Сirculation. 2015;132(20):1891-7. doi: 10.1161/CIRCULATIONAHA.115.016930
  40. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. The New England Journal of Medicine. 2012;367(21):1979-87. doi: 10.1056/NEJMoa1210384
  41. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. The New England Journal of Medicine. 2013;369(15):1406-15. doi: 10.1056/NEJMoa1306638
  42. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. The New England Journal of Medicine. 1999;340(12):901-7. doi: 10.1056/NEJM 199903253401201
  43. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. The New England Journal of Medicine. 2003;348 (15):1425-34. doi: 10.1016/S1062-1458(03)00259-9
  44. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thrombo-embolism. The New England Journal of Medicine. 2012;366(21):1959-67. doi: 10.1056/NEJMoa1114238
  45. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine. 2003;139 (11):893-900. doi: 10.7326/0003-4819-139-11-200312020-00007
  46. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. The New England Journal of Medicine. 2003;349(7): 631-9. doi: 10.1056/NEJMoa035422
  47. Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014; 130(13): 1062-71. doi: 10.1161/CIRCULATIONAHA.114.008828
  48. Pompilio G, Integlia D, Raffetto J, et al. Сomparaive Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis. TH Open. 2020;4(2):e80-e93. doi: 10.1055/s-0040-1709731
  49. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines on the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2020;41(4): 543-603. doi: 10.1093/eurheartj/ehz405
  50. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. The New England Journal of Medicine. 2017;376(13):1211-22. doi: 10.1056/NEJMoa1700518
  51. Mai V, Bertoletti L, Cucherat M, et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS One. 2019;14(4):e0214134. doi: 10.1371/journal.pone.0214134

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Eco-Vector


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».